ScoreWhy is MedCap AB ?
1
High Management Efficiency with a high ROE of 14.67%
2
The company is Net-Debt Free
3
Healthy long term growth as Operating profit has grown by an annual rate 30.65%
4
Flat results in Mar 26
- INTEREST(HY) At SEK 27.7 MM has Grown at 194.68%
5
With ROE of 15.61%, it has a fair valuation with a 4.97 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 17.06%, its profits have risen by 7.9% ; the PEG ratio of the company is 5.2
6
Underperformed the market in the last 1 year
- The stock has generated a return of 17.06% in the last 1 year, much lower than market (OMX Stockholm 30) returns of 30.13%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to MedCap AB should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is MedCap AB for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
MedCap AB
17.06%
-0.18
38.21%
OMX Stockholm 30
30.13%
1.89
15.95%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
20.86%
EBIT Growth (5y)
30.65%
EBIT to Interest (avg)
10.65
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.16
Sales to Capital Employed (avg)
1.30
Tax Ratio
20.23%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
19.53%
ROE (avg)
14.67%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
32
Industry P/E
Price to Book Value
4.97
EV to EBIT
23.77
EV to EBITDA
15.71
EV to Capital Employed
5.30
EV to Sales
3.37
PEG Ratio
5.16
Dividend Yield
NA
ROCE (Latest)
22.32%
ROE (Latest)
15.61%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend7What is working for the Company
OPERATING CASH FLOW(Y)
Highest at SEK 339 MM
RAW MATERIAL COST(Y)
Fallen by -1.69% (YoY
CASH AND EQV(HY)
Highest at SEK 764.8 MM
INVENTORY TURNOVER RATIO(HY)
Highest at 6.37 times
DEBTORS TURNOVER RATIO(HY)
Highest at 6.12 times
-6What is not working for the Company
INTEREST(HY)
At SEK 27.7 MM has Grown at 194.68%
Here's what is working for MedCap AB
Operating Cash Flow
Highest at SEK 339 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (SEK MM)
Cash and Eqv
Highest at SEK 764.8 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Inventory Turnover Ratio
Highest at 6.37 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Debtors Turnover Ratio
Highest at 6.12 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -1.69% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for MedCap AB
Interest
At SEK 27.7 MM has Grown at 194.68%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (SEK MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
